newsfilter
← Latest News
GlobeNewswire·

Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance

A Phase 2 study for NT219 in combination with immunotherapy is being conducted in collaboration with the University of Colorado REHOVOT, Israel, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple